Skip to main content
Contact Us
Subscribe
E-Edition
45°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biofrontera Inc
(NQ:
BFRI
)
0.8101
+0.0511 (+6.73%)
Streaming Delayed Price
Updated: 10:28 AM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biofrontera Inc
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
12 Health Care Stocks Moving In Friday's After-Market Session
February 24, 2023
Via
Benzinga
Biofrontera Inc. to Report Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023
February 22, 2023
Via
ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 18, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 12, 2023
Via
Benzinga
Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
January 09, 2023
Via
ACCESSWIRE
Biofrontera's Return On Capital Employed Overview
December 26, 2022
Via
Benzinga
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2022
January 09, 2023
Via
ACCESSWIRE
Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference
November 30, 2022
From
Biofrontera Inc.
Via
GlobeNewswire
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022
November 28, 2022
From
Biofrontera Inc.
Via
GlobeNewswire
Why ObsEva Shares Are Trading Higher By Over 70%; Here Are 21 Stocks Moving Premarket
November 22, 2022
Gainers ObsEva SA (NASDAQ: OBSV) shares rose 71.9% to $0.2848 in pre-market trading after the company reported the sale of Ebopiprant license agreement to XOMA for up to $113 million.
Via
Benzinga
Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
November 21, 2022
From
Biofrontera Inc.
Via
GlobeNewswire
Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update
November 14, 2022
From
Biofrontera Inc.
Via
GlobeNewswire
Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022
November 10, 2022
From
Biofrontera Inc.
Via
GlobeNewswire
Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG
November 08, 2022
From
Biofrontera Inc.
Via
GlobeNewswire
Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG
October 31, 2022
From
Biofrontera Inc.
Via
GlobeNewswire
Biofrontera Inc. Names Fred Leffler as Chief Financial Officer
October 24, 2022
From
Biofrontera Inc.
Via
GlobeNewswire
Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference
October 20, 2022
From
Biofrontera Inc.
Via
GlobeNewswire
Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference
October 18, 2022
From
Biofrontera Inc.
Via
GlobeNewswire
Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan
October 14, 2022
From
Biofrontera Inc.
Via
GlobeNewswire
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON FRIDAY OCTOBER 14, AND TUESDAY OCTOBER 18, 2022
October 12, 2022
From
Biofrontera Inc.
Via
GlobeNewswire
Biofrontera Inc. Announces Preliminary Product Revenues for the Third Quarter of 2022
October 05, 2022
From
Biofrontera Inc.
Via
GlobeNewswire
Global Laser Therapy Devices Billion Dollar Market Thriving on Growing Demand
October 04, 2022
Palm Beach, FL – October 4, 2022 – FinancialNewsMedia.com News Commentary – The laser therapy market has been having a very health growth trend in recent years and is expected to continue through the...
Via
FinancialNewsMedia
Topics
Death
Economy
Exposures
Death
Economy
Biofrontera Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
September 29, 2022
From
Biofrontera Inc.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
September 20, 2022
Good morning, investor! It's time to start the day with a breakdown of the biggest pre-market stock movers for Tuesday morning!
Via
InvestorPlace
Biofrontera's Return On Capital Employed Overview
September 09, 2022
Benzinga Pro data, Biofrontera (NASDAQ:BFRI) reported Q2 sales of $4.46 million. Earnings fell to a loss of $850 thousand, resulting in a 115.29% decrease from last quarter.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
August 26, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
August 16, 2022
On Tuesday, 37 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
August 15, 2022
On Monday, 31 companies hit new 52-week lows.
Via
Benzinga
Earnings Scheduled For August 12, 2022
August 12, 2022
Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
July 28, 2022
On Thursday, 108 companies set new 52-week lows.
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.